Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for …

Background. The aim of this review is to provide the information about molecular basis of
hypoxia-induced chemoresistance, focusing on the possibility of diagnostic and therapeutic …

Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are
associated with the development of castration-resistant prostate cancer (CRPC), including …

Abstract Interleukin-6 (IL-6) is a pro-inflammatory cytokine involved in the pathogenesis of
various autoimmune and chronic inflammatory diseases. Binding of IL-6 to its receptor (IL …

Here, we describe a novel monoolein-based cubosome formulation engineered for possible
theranostic applications in oncology. The Docetaxel-loaded nanoparticles were stabilized in …

The use of nanotechnology for drug delivery in cancer therapy has raised high expectations.
Additionally, the use of nanomaterials in sensors to extract and detect tumor specific …

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-
sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved …

Background: Docetaxel improves symptoms and survival in metastatic castration-resistant
prostate cancer (CRPC). However,∼ 50% of patients are chemoresistant. This study …

Chronic inflammation is postulated to influence prostate cancer progression. Preclinical
studies have claimed that inflammatory mediators are involved in prostate cancer …